New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 11, 2013
10:12 EDTGWAY, OKSB, ROSE, DISCA, PANW, VRSN, ABT, WPZ, CIEN, SSTK, SLXP, SCOR, AOL, DHI, GMT, MAS, TAP, MRH, OC, AIGOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AIG (AIG) initiated with an Outperform at FBR Capital... AOL (AOL) initiated with a Hold at Cantor... comScore (SCOR) initiated with a Hold at Cantor... D.R. Horton (DHI) initiated with a Buy at BofA/Merrill... GATX Corp. (GMT) initiated with a Buy at Stifel Nicolaus... Masco (MAS) initiated with a Buy at BofA/Merrill... Molson Coors (TAP) initiated with a Buy at Nomura... Montpelier Re (MRH) initiated with a Market Perform at JMP Securities... Owens Corning (OC) initiated with a Buy at BofA/Merrill... Salix (SLXP) initiated with an Outperform at RBC Capital... Shutterstock (SSTK) initiated with a Buy at Cantor... Southwest Bancorp (OKSB) initiated with a Buy at DA Davidson... Rosetta Resources (ROSE) initiated with an Overweight at Stephens... Discovery (DISCA) coverage resumed with a Neutral at JPMorgan... Palo Alto (PANW) initiated with a Neutral at B. Riley Caris... VeriSign (VRSN) initiated with a Neutral at B. Riley Caris... Abbott (ABT) initiated with an Equal Weight at Barclays... Williams Partners (WPZ) initiated with a Buy at Global Hunter... Ciena (CIEN) initiated with a Buy at Maxim... Greenway Medical (GWAY) initiated with a Buy at Sidoti.
News For AIG;SCOR;AOL;DHI;GMT;MAS;TAP;MRH;OC;SLXP;SSTK;OKSB;ROSE;DISCA;PANW;VRSN;ABT;WPZ;CIEN;GWAY From The Last 14 Days
Check below for free stories on AIG;SCOR;AOL;DHI;GMT;MAS;TAP;MRH;OC;SLXP;SSTK;OKSB;ROSE;DISCA;PANW;VRSN;ABT;WPZ;CIEN;GWAY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
July 10, 2014
06:56 EDTSLXPSalix price target raised to $192 from $126 at Piper Jaffray
Subscribe for More Information
06:55 EDTSLXPSalix growth outlook, value compelling, says Stifel
Following Salix's Analyst Day, Stifel believes that Salix's shares offer one of the most compelling growth and value opportunities among specialty drug companies it covers. The firm thinks that data for the company's Xifaxan data was strong and is likely to satisfy the FDA. The firm is upbeat on the company's Cosmo deal and thinks the deal is underappreciated. It keeps a Buy rating on Salix.
July 9, 2014
10:29 EDTSLXPSalix prospects as takeover target debated after inversion deal
Subscribe for More Information
10:19 EDTSLXPSalix targets 3-5 year goal of adjusted net income 32%-37% of revenue
Subscribe for More Information
10:15 EDTSLXPSalix repeats FY14 adjusted EPS view about $6.33, consensus $6.52
Subscribe for More Information
10:02 EDTDISCAOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:13 EDTSLXPOn The Fly: Pre-market Movers
Subscribe for More Information
08:01 EDTSLXPSalix deal suggests not likely to look to sell in near-term, says JMP Securities
After Salix announced a merger with Irish-domiciled Cosmo Technologies, JMP Securities thinks the deal may disappoint investors since it's not immediately materially accretive. The firm contends that the deal suggests that Salix is unlikely to look to sell itself in the near-term ,although it thinks that the company still remains a takeover target. JMP Securities keeps an Outperform rating on the stock.
07:53 EDTSLXPSalix near-term takeout unlikely after inversion deal, says Leerink
Subscribe for More Information
07:46 EDTSLXPSalix tax inversion deal disappointing, says UBS
Subscribe for More Information
07:29 EDTDISCADiscovery CEO sees content consolidation coming, CNBC reports
Subscribe for More Information
06:41 EDTSLXPSalix rationale behind Cosmo deal compelling, says Piper Jaffray
Subscribe for More Information
06:20 EDTSLXPSalix to host conference call
Subscribe for More Information
July 8, 2014
18:18 EDTDISCAU.S. Media sector initiated with a Neutral at Barclays
Subscribe for More Information
18:08 EDTDISCADiscovery initiated with an Overweight at Barclays
Subscribe for More Information
17:04 EDTSLXPSalix to combine with Cosmo Technologies
Salix Pharmaceuticals and Cosmo Pharmaceuticals announced a definitive merger agreement under which Salix will combine with Cosmo Technologies, a subsidiary of Cosmo. Under the terms of the agreement, Salix will become a wholly-owned subsidiary of Irish domiciled Cosmo Tech, which will change its name to Salix Pharmaceuticals, plc and is expected to have its ordinary shares listed and traded on the NASDAQ Global Select Market. The transaction is expected to be modestly accretive to Salix’s EPS in FY16 and increasingly accretive thereafter. Salix Pharmaceuticals, plc will own Cosmo’s U.S. patents for rifamycin MMX, methylene blue MMX and Uceris, and have specified rights of negotiation with respect to all products Cosmo or its affiliates seek to develop or commercialize in the U.S. In addition, Salix Pharmaceuticals, plc will acquire Cosmo’s patents for rifamycin MMX in Canada, specified Latin American countries, India, China, Japan and the rest of the Far East, excluding Australia and New Zealand, and Cosmo’s patents for Uceris in Japan. Upon completion of the merger, shareholders of Salix are expected to own slightly less than 80% of the ordinary shares of Salix Pharmaceuticals, plc and Cosmo is expected to own slightly more than 20%. Shareholders of Salix will receive one ordinary share of Salix Pharmaceuticals, plc in exchange for each share of Salix Pharmaceuticals, Ltd common stock they own at closing. In connection with the merger, Cosmo will continue to supply Uceris to Salix and will also supply rifamycin MMX and methylene blue MMX. Additionally, Cosmo will have the right to designate one director to serve on the board of Salix Pharmaceuticals, plc and will be subject to certain standstill provisions for at least 10 years following the completion of the merger. The transaction, which will be taxable to Salix’s shareholders, is expected to close in Q4.
17:02 EDTSLXPSalix to combine with Cosmo Technologies
Subscribe for More Information
08:13 EDTPANWPalo Alto management to meet with UBS
Subscribe for More Information
07:52 EDTROSERosetta Resources underperformance creates buying opportunity, says KeyBanc
Subscribe for More Information
07:50 EDTROSERosetta Resources price target raised to $66 from $58 at KeyBanc
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use